Company Profile
Since its establishment in Tianjin Binhai New Area in 2010, Cosychem has developed into a technologically leading company in China with more than 50 independent intellectualproperty rights. The company has obtained lSO9001 certification, CNAS accreditation and intellectual property standards compliance certification and is listed as one of the National High-tech Enterprises, National Recognized “Little Giants” Enterprises,National Advantageous Enterprises in the Field of Intellectual Property Rights and Tianjin Intellectual Property Operation Centers (for nucleic acid drugs).
Cosychem pursues technological innovation to promote new productive forces. We are deeply engaged in product pipelines, custom synthesis, compound design and jointdevelopment of diagnostic kits in the field of IVD, Our delivery system of small nucleicacid drugs - GALNAc is among the first tier of domestic product lines and we haverealized the production of phosphoramidite monomer in multi-kilo quantities. As for mRNA, we have a cationic lipid library to develop LNP delivery systems for gene therapy. Cosychem is committed to bio-innovation.and has established the "Joint Laboratory of Nucleic Acid Drug Innovation and Research" with Peking University Health science Center and the "Genomic Nucleic Acid Technology Platform" with Nankai University to setup the downstream application network of nucleic acid drugs, vaccines and so on.
Cosychem has been recognized by industrial funds and has completed financing of over RMB200 million in three years. We will seek further development in the field of nucleic acid drugs by adhering to our philosophy of "going allout, harmonious coexistence, integrity and win-win”.With years of core technology accumulation and industrialization experience, Cosychem will work with upstream and downstream leadingenterprises and authoritative technical experts to solve technical bottlenecks and promote the development of china's nucleic acid industry.